Literature DB >> 18362096

Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions.

Ian R A Mackenzie1, Dean Foti, John Woulfe, Trevor A Hurwitz.   

Abstract

Frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) is the most common neuropathology associated with the clinical syndrome of frontotemporal dementia (FTD). Recently, TDP-43 was identified as the ubiquitinated pathological protein in both FTLD-U and sporadic amyotrophic lateral sclerosis. Although a number of studies have now confirmed that most sporadic and familial cases of FTLD-U are TDP-43 proteinopathies, there are exceptions. We describe six cases of early onset FTD with FTLD-U pathology that was negative for TDP-43, which we refer to as 'atypical' FTLD-U. All cases were sporadic and had very early onset FTD (mean age = 35 years), characterized by severe progressive psychobehavioural abnormalities in the absence of significant aphasia, cognitive-intellectual dysfunction or motor features. The neuropathological features were highly consistent, with small, round, neuronal cytoplasmic inclusions that were immunoreactive for ubiquitin (ub-ir), but negative for tau, alpha-synuclein, intermediate filaments and TDP-43. Cytoplasmic inclusions were most numerous in the neocortex, dentate granule cells and hippocampal pyramidal neurons. Ub-ir neuronal intra-nuclear inclusions were also present in neocortical and hippocampal neurons and had the unusual appearance of straight, curved or twisted filaments. We believe that these cases represent a new entity that is clinically and pathologically distinct from all currently recognized subtypes of FTLD. Moreover, the existence of such cases indicates that the designations of 'FTLD-U' and 'TDP-43 proteinopathy' should not be considered to be synonymous.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362096     DOI: 10.1093/brain/awn061

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  61 in total

Review 1.  Advances in understanding the molecular basis of frontotemporal dementia.

Authors:  Rosa Rademakers; Manuela Neumann; Ian R Mackenzie
Journal:  Nat Rev Neurol       Date:  2012-06-26       Impact factor: 42.937

2.  Caudate atrophy on MRI is a characteristic feature of FTLD-FUS.

Authors:  K A Josephs; J L Whitwell; J E Parisi; R C Petersen; B F Boeve; C R Jack; D W Dickson
Journal:  Eur J Neurol       Date:  2010-03-03       Impact factor: 6.089

3.  Clinical characterization of bvFTD due to FUS neuropathology.

Authors:  Suzee E Lee; William W Seeley; Pardis Poorzand; Rosa Rademakers; Anna Karydas; Christine M Stanley; Bruce L Miller; Katherine P Rankin
Journal:  Neurocase       Date:  2011-11-07       Impact factor: 0.881

4.  TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease.

Authors:  Eileen H Bigio
Journal:  Acta Neuropathol       Date:  2008-06-25       Impact factor: 17.088

Review 5.  TDP-43 and frontotemporal dementia.

Authors:  William T Hu; Murray Grossman
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

6.  Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease.

Authors:  Manuela Neumann; Sigrun Roeber; Hans A Kretzschmar; Rosa Rademakers; Matt Baker; Ian R A Mackenzie
Journal:  Acta Neuropathol       Date:  2009-08-09       Impact factor: 17.088

7.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

Review 8.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

Review 9.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

Review 10.  The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Ian R A Mackenzie; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.